Although it is tempting to hypothesize that severity of inflammation in IBD correlates with CAC survival, it is unclear whether iNOS immunoreactivity, normally regarded as a pro-inflammatory biomarker, would correlate with cancer survival. This evidence concerns the gene NOS2 and cancer.